Loading…
Story
synergy · 1
↔PCOS
Sex hormone imbalance and insulin resistance push each other up: higher androgens in women with polycystic ovary syndrome worsen insulin resistance, and insulin resistance in turn lowers SHBG and raises free androgens. It is a loop that keeps itself turning, which is why both sides need to be managed together.
depletes · 1
Metformin is a first-line drug, cheap, with decades of safety data; one of its costs is that long-term use lowers vitamin B12, generally thought to be by interfering with calcium-dependent absorption at the end of the small intestine. In a large follow-up study, 4.3% of people on metformin had low B12 at 5 years, versus 2.3% on placebo. That is not a reason to stop the drug; it is a reason to monitor.
regulates · 14
A diet heavy in refined carbohydrate and sugary drinks and low in fiber drives repeated post-meal glucose spikes and chronically high insulin. Taylor's twin-cycle hypothesis holds that surplus energy first becomes fat in the liver and pancreas and then wears down the insulin-making beta cells. In DiRECT (Lean 2018), adults with type 2 diabetes diagnosed within 6 years and not on insulin lived on an 825–853 kcal formula total diet replacement for 3–5 months under medical supervision: at 12 months 46% were in remission versus 4% of controls, and 86% of those who lost 15 kg or more.
Taylor's twin-cycle hypothesis holds that when the liver carries too much fat (more than 5% counts as fatty liver), it exports more fat into the blood, the fat settles in the pancreas, the insulin-making beta cells decline, and type 2 diabetes follows; losing enough weight may run the chain in reverse. In DiRECT, the more weight people lost, the more of them went into remission, which fits the hypothesis.
Type 2 diabetes and high blood pressure often occur together and share mechanisms: insulin resistance, damage to the lining of blood vessels, an overactive sympathetic nervous system and an activated renin-angiotensin system; both are parts of the metabolic syndrome. People with diabetes are usually given a stricter blood pressure target than others (ADA 2024).
Obstructive sleep apnea brings repeated drops in oxygen at night, surges of sympathetic activity and broken deep sleep, all of which worsen insulin resistance and make blood sugar harder to control. In turn, obesity and the nerve damage of diabetes make the upper airway more prone to collapse. Weight loss is a lever on both: in the SURMOUNT-OSA trial (2024), the weight-loss drug tirzepatide markedly reduced breathing pauses in people with obesity.
Muscle is the largest destination for blood sugar after a meal; with less muscle, the body handles glucose less well, and insulin resistance and blood sugar can both worsen. In turn, the nerve damage and chronic inflammation of diabetes speed up muscle loss. People losing weight on GLP-1 drugs especially need enough protein and steady strength training to hold on to their muscle.
When muscle contracts, a signal called AMPK moves the glucose transporter GLUT4 to the cell membrane without needing insulin. In the DPP trial (Knowler 2002), the lifestyle group, aiming to lose weight and exercise at least 150 minutes a week, cut its risk of developing type 2 diabetes by 58%, against 31% for metformin; that was the combined effect of diet, weight loss and exercise. In Reynolds 2016, a crossover trial in type 2 diabetes, a 10-minute walk after each of three meals lowered post-meal blood sugar more than a single 30-minute walk at another time.
Estrogen steers fat toward storage under the skin, the pear shape; after it falls, more fat shifts to the abdomen and around the organs, toward the apple shape. More visceral fat brings more insulin resistance, and the risks of metabolic syndrome, type 2 diabetes and fatty liver rise with it.
Insulin works like a key that lets glucose into cells, and insulin resistance means the cells respond to that key less and less. The body makes more and more insulin to compensate, until the pancreas's beta cells can no longer keep up; only then does blood glucose really rise, and type 2 diabetes appears.
When fat builds up where it should not be, in muscle and the liver, its intermediates (diacylglycerol and ceramides) activate signaling molecules such as PKC-theta and JNK, which interfere with insulin signaling. Fructose is readily turned into fat in the liver (de novo lipogenesis), which puts it just upstream of this step.
Controlling blood glucose is a basic step in preventing stroke: chronically high glucose damages the lining of blood vessels and small vessels, adding to the same pathway as high blood pressure, abnormal lipids and smoking rather than opening a separate one. The INTERSTROKE study estimated that 10 modifiable risk factors, these among them, account for about 90% of the population-attributable risk of stroke.
→Blood Work · Routine Chemistry
Early on the road to type 2 diabetes, cells respond less to insulin, and the beta cells of the pancreas compensate by secreting more insulin, holding blood glucose in the normal range. During this stretch fasting glucose is perfectly normal while fasting insulin is already high, so a checkup that measures only glucose misses it; HOMA-IR, calculated from fasting glucose and fasting insulin together, is one of the few visible signals, but it has no agreed diagnostic cut-off.
For people with chronic disease, walking is the lowest-barrier part of managing blood glucose: it needs no equipment and no heavy sweating, because the muscle contractions themselves move glucose out of the blood.
Obesity and insulin resistance lower sex hormone–binding globulin (SHBG), making total testosterone look low while free testosterone may still be normal. The Endocrine Society guideline (Bhasin 2018) calls for taking SHBG into account; low total testosterone in a man with diabetes is not the same as hypogonadism.
Mechanism · Why total testosterone can mislead
Most testosterone in the blood is bound to SHBG, and only about 1–2% is free and able to enter cells and act. Obesity, insulin resistance and type 2 diabetes lower SHBG, so total testosterone looks low while free testosterone may be normal. The Bhasin 2018 guideline calls for accounting for SHBG before deciding whether there is hypogonadism, and the Wu 2010 definition of late-onset hypogonadism does not rest on a single total testosterone result either.
In practice · How to read the lab report
These two sources do not give specific cutoffs for SHBG or free testosterone here. The proper way to test is a morning blood draw, repeated, looking at total testosterone, free testosterone and SHBG together. What you can take away is the order: when a man with diabetes has low total testosterone, check SHBG first, then decide whether he is really deficient.
Safety · Do not rush to testosterone
Do not start testosterone in a man with diabetes on the strength of one low total testosterone result. Bhasin 2018 is a guideline for diagnosing and treating hypogonadism, not a weight-loss tool; address weight, sleep and sleep apnea first, then see whether the criteria for late-onset hypogonadism are met. Nor should this be read as diabetes being caused by low testosterone. The direction is that the metabolic state changes SHBG and makes the lab result look low; a lack of testosterone did not cause the type 2 diabetes.
Blood glucose is one of the few areas where ginseng has moderate-quality human evidence, but "moderate" and "small" belong together: pooled randomized trials show fasting glucose does fall a little, to a statistically significant degree, while HbA1c, fasting insulin and insulin resistance do not improve. Because it really does lower glucose a little, adding it on top of diabetes medication carries a risk of low blood sugar.
contrast · 1
Calling berberine a natural Ozempic misses by a long way: in weight-loss trials semaglutide took off about 15% of body weight on average, while berberine's effect on weight is small. It is closer to a cheap metformin than a stand-in for a GLP-1 drug, and the two do not work through the same pathway.
Mechanism · Two different pathways
Berberine acts mainly on AMPK, the cell's master switch for its energy budget. It makes that switch sense that the cell is short of energy, so the cell shifts toward storing less and burning more glucose and fat. Metformin also works partly through this switch. GLP-1 drugs take a different route: they activate the incretin receptor, which makes insulin release depend on blood glucose, suppresses glucagon, slows stomach emptying and strengthens the feeling of fullness in the brain. The two share no pathway, so neither can be called the natural version of the other.
yin-2008-metabolismNumbers · How big the gap is
Blood glucose: in a small 3-month trial of 36 people newly diagnosed with type 2 diabetes, HbA1c in the berberine group fell from 9.5% to 7.5%, similar to the metformin group. A meta-analysis of 27 randomized trials, mostly from Chinese databases, also found no significant difference between berberine and oral diabetes drugs, though study quality was limited. Weight: semaglutide took off 14.9% of body weight on average in a 68-week trial, against 2.4% on placebo, while berberine's effect on weight is small. So it is closer to a cheap metformin than a replacement for a GLP-1 drug.
lan-2015-jepyin-2008-metabolismIn practice · Testing a natural-version claim
A claim that something is "the natural version" of a drug can be taken apart with two questions: 1. Does it work through the same pathway? If not, there is no substitution, just two things that both lower blood glucose. 2. How far apart are the effects? The same direction is not the same size: both reduce weight, but by very different amounts. Only if both answers pass can you talk about a substitute; passing only the second means the same kind of effect at a lower level, and passing only the first means the same route with less force.